Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.

Suppr

超能文献

作者信息

Illingworth D R, Erkelens D W, Keller U, Thompson G R, Tikkanen M J

机构信息

Department of Medicine-L465, Oregon Health Sciences University, Portland 97201.

出版信息

Lancet. 1994 Jun 18;343(8912):1554-5. doi: 10.1016/s0140-6736(94)92945-9.

DOI:10.1016/s0140-6736(94)92945-9

PMID:7911877

Abstract

摘要

相似文献

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.

Lancet. 1994 Jun 18;343(8912):1554-5. doi: 10.1016/s0140-6736(94)92945-9.

Efficacy of low-density-lipoprotein lowering with statins.

Lancet. 1994 Sep 3;344(8923):683.

Efficacy of low-density-lipoprotein lowering with statins.

Lancet. 1994 Sep 3;344(8923):683.

Efficacy of low-density-lipoprotein lowering with statins.

Lancet. 1994 Sep 3;344(8923):683-4.

Efficacy of low-density-lipoprotein lowering with statins.

Lancet. 1994 Sep 3;344(8923):684.

Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.

Lab Anim. 1992 Oct;26(4):269-80. doi: 10.1258/002367792780745689.

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

Br J Clin Pharmacol. 1993 Mar;35(3):284-9.

Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.

Am J Cardiol. 1998 Feb 26;81(4A):1B-6B. doi: 10.1016/s0002-9149(98)00030-7.

Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.

J Hypertens. 1996 Jan;14(1):115-21.

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.

Drug Saf. 1996 Jan;14(1):11-24. doi: 10.2165/00002018-199614010-00003.

引用本文的文献

HIF stabilization inhibits renal epithelial cell migration and is associated with cytoskeletal alterations.

Sci Rep. 2018 Jun 22;8(1):9497. doi: 10.1038/s41598-018-27918-9.

Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.

Eur J Clin Pharmacol. 2013 Jun;69(6):1269-74. doi: 10.1007/s00228-012-1453-9. Epub 2012 Dec 22.

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

Br J Clin Pharmacol. 2007 Sep;64(3):346-52. doi: 10.1111/j.1365-2125.2007.02892.x. Epub 2007 Apr 18.

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Pharm Res. 2007 Feb;24(2):239-47. doi: 10.1007/s11095-006-9159-2. Epub 2006 Dec 20.

Model-based development of gemcabene, a new lipid-altering agent.

AAPS J. 2005 Oct 7;7(3):E513-22. doi: 10.1208/aapsj070352.

Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003.

Br J Clin Pharmacol. 2005 Nov;60(5):543-51. doi: 10.1111/j.1365-2125.2005.02478.x.

Suboptimal choices and dosing of statins at start of therapy.

Br J Clin Pharmacol. 2005 Jul;60(1):83-9. doi: 10.1111/j.1365-2125.2005.02367.x.

Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe.

Eur J Clin Pharmacol. 2004 Sep;60(7):503-11. doi: 10.1007/s00228-004-0801-9.

Benefits and risks of simvastatin in patients with familial hypercholesterolaemia.

Drug Saf. 2003;26(11):769-86. doi: 10.2165/00002018-200326110-00003.

Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.

Br J Clin Pharmacol. 2002 Mar;53(3):284-95. doi: 10.1046/j.0306-5251.2001.01181.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验